Tempus AI (NASDAQ:TEM) Reaches New 52-Week High - Should You Buy?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) shares hit a new 52-week high during trading on Thursday . The company traded as high as $80.70 and last traded at $80.24, with a volume of 7026374 shares traded. The stock had previously closed at $73.88.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TEM. Stifel Nicolaus downgraded Tempus AI from a "buy" rating to a "hold" rating and upped their price objective for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Bank of America upped their price objective on Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a research note on Friday, December 13th. TD Cowen restated a "buy" rating and set a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Wolfe Research assumed coverage on Tempus AI in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective for the company. Finally, Needham & Company LLC reissued a "buy" rating and issued a $56.00 price target on shares of Tempus AI in a research note on Tuesday, January 14th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $58.55.

Tempus AI Stock Down 8.4 %

The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The company has a fifty day moving average price of $47.46 and a two-hundred day moving average price of $50.72.

Insider Activity

In other news, EVP Andrew Polovin sold 1,130 shares of the company's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $40.23, for a total value of $45,459.90. Following the completion of the sale, the executive vice president now owns 244,955 shares in the company, valued at $9,854,539.65. This represents a 0.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director David R. Epstein sold 620 shares of the company's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the sale, the director now owns 27,894 shares of the company's stock, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,401,779 shares of company stock worth $115,707,361 over the last 90 days.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently modified their holdings of TEM. Clarus Group Inc. purchased a new stake in Tempus AI during the third quarter valued at about $283,000. International Assets Investment Management LLC raised its holdings in shares of Tempus AI by 141,400.0% during the third quarter. International Assets Investment Management LLC now owns 70,750 shares of the company's stock valued at $4,004,000 after acquiring an additional 70,700 shares during the period. Dakota Wealth Management purchased a new stake in shares of Tempus AI in the 3rd quarter valued at approximately $1,185,000. Janney Capital Management LLC acquired a new position in Tempus AI in the 3rd quarter worth approximately $385,000. Finally, Vestor Capital LLC purchased a new position in Tempus AI during the 3rd quarter worth approximately $153,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.